This is a pharmacokinetic study for \[14C\]TGRX-678 on mass balance to evaluate distribution, metabolism and excretion of TGRX-678, a tyrosine kinase inhibitor indicated for treatment of chronic myeloid leukemia.
Phase:
PHASE1
Details
Lead Sponsor:
Shenzhen TargetRx, Inc.
Collaborator:
The First Affiliated Hospital of Soochow University